Back to top

Therapeutic Oligonucleotides

Therapeutic Oligonucleotides
 
 
Several antisense oligonucleotide drugs have been approved by the regulatory agencies (FDA, EMEA) in the past two decades. Oligonucleotide-based therapeutics generally are a hot topic in research and development as they open the door for the treatment of a broad range of diseases that cannot be treated differently.


 
 

Know-How & Expertise

 
 

Microsynth, well known for 30 years of experience in the synthesis of modified oligonucleotides, is handling the early phase research and development projects, enabling clients to benefit from

  • a high level of expertise and experience in the synthesis of oligonucleotides (ASOs, gapmers, siRNAs) for drug discovery
  • the best approach for the chemical synthesis using a broad portfolio of modifications (e.g. LNA, MOE, GalNAc, S-cEt)
  • the fastest supply available, delivering products at exceptional speed
  • sustainable and cost-efficient setup, from infrastructure to processes and systems
  • fast, flexible and reliable service from quote to delivery
 
 

Service Offering

 
 
Microsynth is your ideal partner for drug discovery programes for oligonucleotides APIs. In collaboration with Bachem we can support your whole development drug development program up to commercialization.

 

Research & development

  • fast turnaround times
  • flexible synthesis of a broad portfolio of therapeutic oligonucleotide drug candidates
  • hands-on know-how in challenging and custom modifications
  • instant synthesis of ASO libraries for screening (ug-mg)

 

Get a Quote

 
 
When you collaborate with Microsynth, we share our experience and knowledge, respond to your needs in a timely manner and give you undivided attention. Interested to discuss your contract manufacturing need with an expert or to receive a quote? Then, please fill in our contact form.